Research into dementia treatment receives boost with new $2.8 million grant
Research of a potential new treatment for dementia is going to receive a massive boost with a a five-year, $2.8 million grant.
The grant was received by the Sanders-Brown Center on Aging. The research involves the drug candidate, called MW150, which targets dysregulated brain inflammation driven by a stress-activated protein called p38aMAPK.
Scientists explain that the particular research is novel as it is exploring efficacy in treating more than one form of dementia at the same time. Scientists explain that it is extremely rare to see someone with only one type of dementia pathology in the brain and so a drug that can target more than one forms of dementia would be a massive step towards our fight against dementia.
As chronic neuroinflammation is a common feature seen early in both VCID and Alzheimer’s disease progression, Van Eldik’s work will test the idea that excessive inflammation in the brain driven by p38aMAPK worsens dementia symptoms and is therefore a good target for therapeutic intervention.
The study will use novel mouse models and Van Eldik’s recently developed drug candidateMW150, which (unlike most other dementia drug candidates) is able to cross the blood-brain barrier, increasing its potential therapeutic impact.
According to researchers this study is a key first step to understanding how to someday prevent or treat the growing number of elderly individuals afflicted by dementia with complex co-morbid pathologies.